Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

NCT00358020 is registered in ClinicalTrials.gov with University of Turin, Italy as lead sponsor.

NCT NCT00358020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00358020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
Lead sponsor
University of Turin, Italy
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
December 31, 2008
Enrollment
30
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma